<div class="slide7">
	<h1>Xarelto<sup>&reg;</sup> Significantly Reduces<br/>ICH and Fatal Bleeding Events</h1>
	<p>Active treatment with once-daily Xarelto vs warfarin in AF patients shows similar overall<br/>bleeding in the composite of major and non-major clinically relevant bleeding events<em>Reduce the risk of the most critical bleeds in your AF patients<sup>12</sup></em></p>
	
	<dl class="diamonds">
		<dt>50%<span>RRR</span></dt>
		<dd><p><em>Reduced fatal bleeding events </em>Xarelto (0.24) vs warfarin (0.48), <i>P</i>=0.003<sup>12</sup></p></dd>
		<dt>33%<span>RRR</span></dt>
		<dd><p><em>Fewer ICH events </em>Xarelto (0.49) vs warfarin (0.74), <i>P</i>=0.019<sup>12</sup></p></dd>
		<dt>31%<span>RRR</span></dt>
		<dd><p><em>Fewer critical organ bleeding events </em>Xarelto (0.82) vs warfarin (1.18), <i>P</i>=0.007<sup>12</sup></p></dd>
	</dl>
	<div class="ref zoom" id="safety_zoom">
		<p>All values are expressed as event rate per 100 patient-years. Patients on Xarelto had significant<br /> increases in the following major bleeding events:.a ≥2 g/dL fall in haemoglobin (2.8% vs. 2.3%, P=0.019) and transfusions (1.7% vs. 1.3%, P=0.044).</p>
		<p><strong>Major bleeding</strong>: bleeding associated with a ≥2 g/dL fall in haemoglobin or requirement for transfusion of ≥2 units of packed red blood cells or .whole blood (clinically overt bleeding); the involvement of a critical site; or a fatal outcome.</p>
		<p><strong>Non-major clinically relevant bleeding</strong>: overt bleeding not meeting the criteria for major bleeding but associated with medical intervention; unscheduled contact with a physician; temporary study drug cessation; pain; or impairment of daily activities. ICH=intracranial haemmorhagic.</p>
	</div>
</div>
